UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2017

or

[  ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission File Number 0-29466

 

         National Research Corporation         

(Exact name of Registrant as specified in its charter)

 

Wisconsin		47-0634000
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

 

	1245 Q Street, Lincoln, Nebraska          68508
	(Address of principal executive offices) (Zip Code)

 

	(402) 475-2525
	(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐    (Do not check if a smaller reporting company)	Smaller reporting company	☐
		Emerging growth company	☐

    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐
 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.)

Yes ☐    No  ☒ 

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

 

Class A Common Stock, $.001 par value, outstanding as of April 28, 2017: 20,925,598 shares

Class B Common Stock, $.001 par value, outstanding as of April 28, 2017: 3,543,463 shares

 

 

NATIONAL RESEARCH CORPORATION

 

FORM 10-Q INDEX

 

For the Quarter Ended March 31, 2017

 

			Page No.
PART I.	FINANCIAL INFORMATION
	Item 1.	Financial Statements
		Condensed Consolidated Balance Sheets	4
		Condensed Consolidated Statements of Income	5
		Condensed Consolidated Statements of Comprehensive Income	6
		Condensed Consolidated Statements of Cash Flows	7
		Notes to Condensed Consolidated Financial Statements	8-15
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16-21
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
	Item 4.	Controls and Procedures	21
PART II.	OTHER INFORMATION
	Item 1A.	Risk Factors	22
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
	Item 6.	Exhibits	22
	Signatures		23
	Exhibit Index		24

 

 

Special Note Regarding Forward-Looking Statements

 

Certain matters discussed in this Quarterly Report on Form 10-Q are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can generally be identified as such because the context of the statement includes phrases such as National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), “believes,” “expects,” or other words of similar import. Similarly, statements that describe the Company’s future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties which could cause actual results or outcomes to differ materially from those currently anticipated. Factors that could affect actual results or outcomes include, without limitation, the following factors:

 

●

The possibility of non-renewal of the Company’s client service contracts and retention of key clients;

 

●

The Company’s ability to compete in its markets, which are highly competitive, and the possibility of increased price pressure and expenses;

 

●

The effects of an economic downturn;

 

●

The impact of consolidation in the healthcare industry;

 

●

The impact of federal healthcare reform legislation or other regulatory changes;

 

●

The Company’s ability to attract and retain key managers and other personnel;

 

●

The possibility that the Company’s intellectual property and other proprietary information technology could be copied or independently developed by its competitors;

 

●

The possibility that the Company could be subject to security breaches or computer viruses; and

 

●

The factors set forth under the caption “Risk Factors” in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as such section may be updated or supplemented by Part II, Item 1A of the Company’s subsequently filed Quarterly Reports on Form 10-Q (including this Report).

 

Shareholders, potential investors and other readers are urged to consider these and other factors in evaluating the forward-looking statements, and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included are only made as of the date of this Quarterly Report on Form 10-Q and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

 

 

PART I – Financial Information

ITEM 1. Financial Statements

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts and par value)

		March 31, 2017				December 31, 2016
			(unaudited)
Assets
Current assets:
Cash and cash equivalents		$	34,664			$	33,021
Trade accounts receivable, less allowance for doubtful accounts of $165 and $169 in 2017 and 2016, respectively			13,524				10,864
Unbilled revenue			1,923				1,546
Prepaid expenses			2,237				1,585
Income tax receivable			24				14
Other current assets			11				35
Total current assets			52,383				47,065
Property and equipment, net			12,133				11,806
Intangible assets, net			2,977				3,124
Goodwill			57,881				57,861
Other			685				768
Total assets		$	126,059			$	120,624
Liabilities and Shareholders’ Equity
Current liabilities:
Current portion of notes payable		$	2,499			$	2,683
Accounts payable			817				765
Accrued wages, bonus and profit sharing			3,306				4,543
Accrued expenses			2,658				3,069
Current portion of capital lease obligations			101				82
Income taxes payable			3,563				662
Dividends payable			4,218				4,213
Deferred revenue			17,189				15,497
Total current liabilities			34,351				31,514
Notes payable, net of current portion			225				857
Deferred income taxes			5,073				4,670
Other long term liabilities			838				777
Total liabilities			40,487				37,818
Shareholders’ equity:
Preferred stock, $0.01 par value; authorized 2,000,000 shares, none issued			--				--
Class A Common stock, $0.001 par value; authorized 60,000,000 shares, issued 25,753,828 in 2017 and 25,656,760 in 2016, outstanding 20,916,570 in 2017 and 20,891,069 in 2016			26				26
Class B Common stock, $0.001 par value; authorized 80,000,000 shares, issued 4,320,875 in 2017 and 4,308,875 in 2016, outstanding 3,543,463 in 2017 and 3,539,931 in 2016			4				4
Additional paid-in capital			48,787				46,725
Retained earnings			73,810				71,507
Accumulated other comprehensive loss			(2,508	)			(2,626	)
Treasury stock, at cost; 4,837,258 Class A shares, 777,412 Class B shares in 2017 and 4,765,691 Class A shares, 768,944 Class B shares in 2016			(34,547	)			(32,830	)
Total shareholders’ equity			85,572				82,806
Total liabilities and shareholders’ equity		$	126,059			$	120,624

 

See accompanying notes to condensed consolidated financial statements

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except for per share amounts, unaudited)

 

 

		Three months ended March 31
		2017				2016
Revenue		$	30,276			$	27,870
Operating expenses:
Direct			12,500				11,539
Selling, general and administrative			6,686				7,357
Depreciation and amortization			1,106				968
Total operating expenses			20,292				19,864
Operating income			9,984				8,006
Other income (expense):
Interest income			14				11
Interest expense			(27	)			(85	)
Other, net			9				74
Total other income (expense)			(4	)			--
Income before income taxes			9,980				8,006
Provision for income taxes			3,459				2,500
Net income		$	6,521			$	5,506
Earnings Per Share of Common Stock:
Basic Earnings Per Share:
Class A		$	0.15			$	0.13
Class B		$	0.93			$	0.79
Diluted Earnings Per Share:
Class A		$	0.15			$	0.13
Class B		$	0.91			$	0.77
Dividends Per Share of Common Stock:
Class A		$	0.10			$	0.08
Class B		$	0.60			$	0.48
Weighted average shares and share equivalents outstanding:
Class A - basic			20,737				20,710
Class B - basic			3,513				3,489
Class A - diluted			21,245				21,012
Class B - diluted			3,576				3,549

 

See accompanying notes to condensed consolidated financial statements

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, unaudited)

 

 

		Three months ended March 31,
		2017				2016
Net income		$	6,521			$	5,506
Other comprehensive income (loss):
Foreign currency translation adjustment		$	118			$	874
Other comprehensive income (loss)		$	118			$	874
Comprehensive Income		$	6,639			$	6,380

 

See accompanying notes to condensed consolidated financial statements.

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, unaudited)

 

		Three months ended
		March 31,
		2017				2016
Cash flows from operating activities:
Net income		$	6,521			$	5,506
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			1,106				968
Deferred income taxes			403				761
Reserve for uncertain tax positions			44				(105	)
Non-cash share-based compensation expense			450				536
Net changes in assets and liabilities:
Trade accounts receivable			(2,647	)			(4,167	)
Unbilled revenue			(374	)			33
Prepaid expenses			(540	)			(254	)
Accounts payable			207				469
Accrued expenses, wages, bonuses and profit sharing			(1,606	)			58
Income taxes receivable and payable			2,890				(2,451	)
Deferred revenue			1,689				3,013
Net cash provided by operating activities			8,143				4,367
Cash flows from investing activities:
Purchases of property and equipment			(1,425	)			(1,084	)
Net cash used in investing activities			(1,425	)			(1,084	)
Cash flows from financing activities:
Payments on notes payable			(816	)			(594	)
Payments on capital lease obligations			(27	)			(25	)
Cash paid for non-controlling interest			--				(2,000	)
Proceeds from exercise of stock options			--				547
Payment of employee payroll tax withholdings on share-based awards exercised			(105	)			(147	)
Payment of dividends on common stock			(4,213	)			(18,440	)
Net cash used in financing activities			(5,161	)			(20,659	)
Effect of exchange rate changes on cash			86				597
Change in cash and cash equivalents			1,643				(16,779	)
Cash and cash equivalents at beginning of period			33,021				42,145
Cash and cash equivalents at end of period		$	34,664			$	25,366
Supplemental disclosure of cash paid for:
Interest, net of capitalized amounts		$	24			$	83
Income taxes		$	122			$	4,361
Supplemental disclosure of non-cash investing and financing activities:
Capital lease obligations originated for property and equipment		$	64			$	--
Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans		$	1,612			$	--

 

See accompanying notes to condensed consolidated financial statements.

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

 

1.	BASIS OF CONSOLIDATION AND PRESENTATION

 

National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. The Company’s solutions enable its clients to understand the voice of the customer with greater clarity, immediacy and depth.

 

The Company’s six operating segments are aggregated into one reporting segment because they have similar economic characteristics and meet the other aggregation criteria from the Financial Accounting Standards Board (“FASB”) guidance on segment disclosure. The six operating segments are Experience, The Governance Institute, Market Insights, Transparency, NRC Health Canada and Transitions (formerly Connect), which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations.

 

The condensed consolidated balance sheet of the Company at December 31, 2016, was derived from the Company’s audited consolidated balance sheet as of that date. All other financial statements contained herein are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) the Company considers necessary for a fair presentation of financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States.

 

Information and footnote disclosures included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in the Company’s Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2017.

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, National Research Corporation Canada, doing business as NRC Health Canada. The condensed consolidated statement of income for the three months ended March 31, 2016 also included Customer-Connect LLC.  Customer-Connect LLC became a wholly-owned subsidiary in March 2016 and was previously a variable interest entity for which NRC Health was deemed the primary beneficiary. On June 30, 2016, Customer-Connect LLC was dissolved. All significant intercompany transactions and balances have been eliminated.

 

The functional currency of the Company’s foreign subsidiary, National Research Corporation Canada, doing business as NRC Health Canada, is the subsidiary’s local currency. The Company translates the assets and liabilities of its foreign subsidiary at the period-end rate of exchange and its foreign subsidiary’s income statement balances at the average rate prevailing during the period. The Company records the resulting translation adjustment in accumulated other comprehensive loss, a component of shareholders’ equity. Since the undistributed earnings of the Company’s foreign subsidiary are considered to be indefinitely reinvested, no taxes were provided for on currency translation adjustments arising from converting the investment denominated in a foreign currency to U.S. dollars. Gains and losses related to transactions denominated in a currency other than the subsidiary’s local currency and short-term intercompany accounts are included in other income (expense) in the condensed consolidated statements of income.

 

Reclassifications

 

Certain reclassifications have been made to the 2016 financial statement information to conform to the 2017 financial statement presentation. There was no impact on the previously reported net income and earnings per share.

 

Fair Value Measurements

 

The Company’s valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect the Company’s market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; and (3) Level 3 Inputs—unobservable inputs.

 

Commercial paper included in cash equivalents is valued at amortized cost, which approximates fair value due to its short-term nature. These are included as a Level 2 measurement in the table below.

 

The following details the Company’s financial assets and liabilities within the fair value hierarchy at March 31, 2017 and December 31, 2016:

 

Fair Values Measured on a Recurring Basis

 

		Level 1				Level 2				Level 3				Total
		(In thousands)
As of March 31, 2017
Money Market Funds		$	11,006			$	--			$	--			$	11,006
Commercial Paper			--				23,584				--				23,584
Total		$	11,006			$	23,584			$	--			$	34,590
As of December 31, 2016
Money Market Funds		$	11,200			$	--			$	--			$	11,200
Commercial Paper			--				21,450				--				21,450
Total		$	11,200			$	21,450			$	--			$	32,650

 

The Company’s long-term debt is recorded at historical cost. The following are the carrying amounts and estimated fair values, using a Level 2 discounted cash flow analysis based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit risk:

 

		March 31, 2017				December 31, 2016
		(In thousands)
Total carrying amounts of long-term debt		$	2,724			$	3,540
Estimated fair value of long-term debt		$	2,718			$	3,533

 

The Company believes that the carrying amounts of trade accounts receivable, accounts payable and accrued expenses approximate their fair value due to the short maturity of those instruments. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes goodwill and non-financial long-lived assets, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of March 31, 2017, and December 31, 2016, there was no indication of impairment related to the Company’s non-financial assets.

 

 

2.	INCOME TAXES

 

The effective tax rate for the three-month period ended March 31, 2017 increased to 34.7% compared to 31.2% for the same period in 2016. The increase in the effective tax rate for the three-month period ending March 31, 2017 was mainly due to higher tax benefits in 2016 from the exercise of options and vesting of restricted stock of $166,000, as well as United States federal tax examination adjustments decreasing tax expense by $48,000 in 2016. The United States federal tax examination for the tax year ended December 31, 2013 was completed in the three-month period ended March 31, 2016.

 

3.	NOTES PAYABLE

 

The Company’s term note is payable in monthly installments of $212,468. Borrowings under the term note bear interest at an annual rate of 3.12%. The outstanding balance of the term note at March 31, 2017 was $2.7 million.

 

The Company also has a revolving credit note that was renewed in June 2016 to extend the term to
June 30, 2017. The maximum aggregate amount available under the revolving credit note is $6.5 million, subject to a borrowing base equal to 75.0% of the Company’s eligible accounts receivable. Borrowings under the revolving credit note bear interest at a variable annual rate, with three rate options at the discretion of management as follows: (1) 2.5% plus the daily reset one-month London Interbank Offered Rate (“LIBOR”) or (2) 2.2% plus the one-, two- or three- month LIBOR rate, or (3) the bank’s one-, two, three, six, or twelve month Money Market Loan Rate. As of March 31, 2017 the revolving credit note did not have a balance. According to the borrowing base requirements, the Company had the capacity to borrow $6.5 million as of March 31, 2017.

 

The term note and revolving credit note are secured by certain of the Company’s assets, including the Company’s land, building, trade accounts receivable and intangible assets. The term note and revolving credit note contain various restrictions and covenants applicable to the Company, including requirements that the Company maintain certain financial ratios at prescribed levels and restrictions on the ability of the Company to consolidate or merge, create liens, incur additional indebtedness or dispose of assets. As of March 31, 2017, the Company was in compliance with its financial covenants.

 

4.	SHARE-BASED COMPENSATION

 

The Company measures and recognizes compensation expense for all share-based payments based on the grant-date fair value of those awards. All of the Company’s existing stock option awards and unvested stock awards have been determined to be equity-classified awards.

 

The Company’s 2001 Equity Incentive Plan provided for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of class A common stock and 300,000 shares of class B common stock. Stock options granted could have been either nonqualified or incentive stock options. Stock options vest over one to five years following the date of grant and option terms are generally five to ten years following the date of grant.

 

The Company’s 2004 Non-Employee Director Stock Plan, as amended (the “2004 Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of class A common stock and 500,000 shares of class B common stock. The 2004 Director Plan provides for grants of nonqualified stock options to each director of the Company who is not employed by the Company. On the date of each annual meeting of shareholders of the Company, options to purchase 36,000 shares of class A common stock and 6,000 shares of class B common stock are granted to directors that are elected or retained as a director at such meeting. Stock options vest one year following the date of grant and option terms are generally ten years following the date of grant, or three years in the case of termination of the outside director’s service.

 

The Company’s 2006 Equity Incentive Plan provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of class A common stock and 300,000 shares of class B common stock. Stock options granted may be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally five to ten years following the date of grant.

 

 

The Company granted options to purchase 119,917 shares of the Company’s class A common stock and 19,986 shares of the class B common stock during the three-month period ended March 31, 2017. Options to purchase shares of common stock were granted with exercise prices equal to the fair value of the common stock on the date of grant. The fair value of the stock options granted was estimated using a Black-Scholes valuation model with the following assumptions:

 

		2017								2016
		Class A				Class B				Class A				Class B
Expected dividend yield at date of grant			2.87	%			7.99	%			3.02	%			8.12	%
Expected stock price volatility			32.20	%			27.18	%			34.61	%			31.77	%
Risk-free interest rate			2.33	%			2.33	%			2.12	%			2.12	%
Expected life of options (in years)			8				8				8				8

 

The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of the Company’s common stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years the Company estimates that options will be outstanding. The Company considers groups of associates that have similar historical exercise behavior separately for valuation purposes.

 

The following table summarizes stock option activity under the Company’s 2001 and 2006 Equity Incentive Plans and the 2004 Director Plan for the three months ended March 31, 2017:

 

		Number of Options				Weighted Average Exercise Price				Weighted Average Remaining Contractual Terms (Years)				Aggregate Intrinsic Value (In thousands)
Class A
Outstanding at December 31, 2016			1,705,483			$	12.31
Granted			119,917			$	18.80
Exercised			(97,068	)		$	13.10							$	590
Forfeited			--				--
Outstanding at March 31, 2017			1,728,332			$	12.72				6.00			$	12,064
Exercisable at March 31, 2017			1,195,077			$	11.49				4.76			$	9,807
Class B
Outstanding at December 31, 2016			250,493			$	29.70
Granted			19,986			$	40.54
Exercised			(12,000	)		$	28.41							$	142
Forfeited			--				--
Outstanding at March 31, 2017			258,479			$	30.60				6.38			$	2,402
Exercisable at March 31, 2017			170,550			$	27.52				5.14			$	2,140

 

As of March 31, 2017, the total unrecognized compensation cost related to non-vested stock option awards was approximately $1.2 million and $179,000 for class A and class B common shares, respectively, which is expected to be recognized over a weighted average period of 3.86 years and 3.57 years for class A and class B common stock shares, respectively.

 

 

The following table summarizes information regarding non-vested stock granted to associates under the 2001 and 2006 Equity Incentive Plan for the three months ended March 31, 2017:

 

		Class A Shares Outstanding				Class A Weighted Average Grant Date Fair Value Per Share				Class B Shares Outstanding				Class B Weighted Average Grant Date Fair Value Per Share
Outstanding at December 31, 2016			174,487			$	13.93				29,081			$	37.21
Granted			--				--				--				--
Vested			--				--				--				--
Forfeited			--				--				--				--
Outstanding at March 31, 2017			174,487			$	13.93				29,081			$	37.21

 

As of March 31, 2017, the total unrecognized compensation cost related to non-vested stock awards was approximately $1.6 million and is expected to be recognized over a weighted average period of 2.88 years.

 

5.	GOODWILL AND OTHER INTANGIBLE ASSETS

 

The following represents a summary of changes in the Company’s carrying amount of goodwill for the three months ended March 31, 2017:

 

		(In thousands)
Balance as of December 31, 2016		$	57,861
Foreign currency translation			20
Balance as of March 31, 2017		$	57,881

 

Intangible assets consisted of the following:

 

		March 31, 2017				December 31, 2016
		(In thousands)
Non-amortizing other intangible assets:
Trade name		$	1,191			$	1,191
Amortizing other intangible assets:
Customer related			9,332				9,331
Technology			1,110				1,110
Trade name			1,572				1,572
Total other intangible assets			13,205				13,204
Accumulated amortization			(10,228	)			(10,080	)
Other intangible assets, net		$	2,977			$	3,124

 

 

6.	PROPERTY AND EQUIPMENT

 

		March 31, 2017				December 31, 2016
		(In thousands)
Property and equipment		$	39,186			$	37,890
Accumulated depreciation			(27,053	)			(26,084	)
Property and equipment, net		$	12,133			$	11,806

 

 

7.	EARNINGS PER SHARE

 

Net income per share of class A common stock and class B common stock is computed using the two-class method. Basic net income per share is computed by allocating undistributed earnings to common shares and using the weighted-average number of common shares outstanding during the period.

 

Diluted net income per share is computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.

 

The liquidation rights and the rights upon the consummation of an extraordinary transaction are the same for the holders of class A common stock and class B common stock. Other than share distributions and liquidation rights, the amount of any dividend or other distribution payable on each share of class A common stock will be equal to one-sixth (1/6^th) of the amount of any such dividend or other distribution payable on each share of class B common stock. As a result, the undistributed earnings for each period are allocated based on the contractual participation rights of the class A and class B common stock as if the earnings for the period had been distributed.

 

 

At March 31, 2017 and 2016, the Company had 128,530 and 502,269 options of class A shares and 49,320 and 65,071 options of class B shares, respectively, which have been excluded from the diluted net income per share computation because the exercise or grant price exceeded the fair market value. At March 31, 2017, an additional 123,274 options of class A shares were excluded as their inclusion would be anti-dilutive. At March 31, 2016, an additional 255,740 options of class A shares and 28,765 of class B shares were excluded as their inclusion would be anti-dilutive.

 

		For the Three Months Ended March 31, 2017								For the Three Months Ended March 31, 2016
		Class A Common Stock				Class B Common Stock				Class A Common Stock				Class B Common Stock
		(In thousands, except per share data)
Numerator for net income per share - basic:
Net income		$	3,234			$	3,287			$	2,735			$	2,771
Allocation of distributed and undistributed income to unvested restricted stock shareholders			(27	)			(27	)			(23	)			(22	)
Net income attributable to common shareholders		$	3,207			$	3,260			$	2,712			$	2,749
Denominator for net income per share - basic:
Weighted average common shares outstanding - basic			20,737				3,513				20,710				3,489
Net income per share – basic		$	0.15			$	0.93			$	0.13			$	0.79
Numerator for net income per share - diluted:
Net income attributable to common shareholders for basic computation		$	3,207			$	3,260			$	2,712			$	2,749
Denominator for net income per share - diluted:
Weighted average common shares outstanding - basic			20,737				3,513				20,710				3,489
Weighted average effect of dilutive securities – stock options			508				63				302				60
Denominator for diluted earnings per share – adjusted weighted average shares			21,245				3,576				21,012				3,549
Net income per share – diluted		$	0.15			$	0.91			$	0.13			$	0.77

 

8.     RELATED PARTY     

 

A director of the Company serves as an officer of Ameritas Life Insurance Corp. (“Ameritas”). In connection with the Company’s regular assessment of its insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, the Company purchases dental and vision insurance for certain of its associates from Ameritas. The total value of these purchases was $58,000 for each of the three-month periods ended March 31, 2017 and 2016.

 

Mr. Hays, the Chief Executive Officer, majority shareholder and director of the Company, is an owner of 14% of the equity interest of Nebraska Global Investment Company LLC (“Nebraska Global”).  The Company, directly or indirectly through its former subsidiary Customer-Connect LLC, purchased certain services from Nebraska Global, primarily consisting of software development services.  The total value of these purchases were $215,000 in the three month period ended March 31, 2016. There were no purchases from Nebraska Global in 2017.

 

9.     RECENT ACCOUNTING PRONOUNCEMENTS

 

In May 2014, the FASB issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”).  ASU 2014-09 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in accounting principles generally accepted in the United States when it becomes effective. The standard is effective for annual and interim reporting periods in fiscal years beginning after December 15, 2017, with early adoption allowed for years beginning after December 15, 2016. An entity may choose to adopt ASU 2014-09 either retrospectively or through a cumulative effect adjustment as of the start of the first period for which it applies the standard.  The Company is currently in the process of evaluating the impact that this new guidance will have on its consolidated financial statements and expects to adopt the guidance beginning January 1, 2018 through the retrospective transition method. We are in the process of developing and testing changes to our processes and systems. The Company currently expects the most significant changes to result from deferring commissions and recognizing the expense over the estimated life of the client relationship rather than expensing as incurred, which is the Company’s current practice, and estimating variable consideration at the outset of the contract. 

 

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability and a right-to-use asset for all leases, including operating leases, with a term greater than twelve months on its balance sheet. This ASU is effective in fiscal years beginning after December 15, 2018, with early adoption permitted, and requires a modified retrospective transition method. The Company is currently in the process of evaluating the impact that this new guidance will have on its consolidated financial statements.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326):  Measurement of Credit Losses on Financial Instruments.  This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance is effective for annual reporting periods beginning after December 15, 2019 and interim periods within those fiscal years. The Company believes its adoption will not significantly impact the Company’s results of operations and financial position.

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments which eliminates the diversity in practice related to eight cash flow classification issues.  This ASU is effective for the Company on January 1, 2018 with early adoption permitted.  The Company believes its adoption will not significantly impact the Company’s results of operations and financial position.

 

In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Asset Other Than Inventory “ASU 2016-16”), which requires entities to recognize the tax consequences of intercompany asset transfers other than inventory transfers in the period in which the transfer takes place. ASU 2016-16 is effective for fiscal years and interim periods within fiscal years beginning after December 15, 2017. ASU 2016-16 is to be adopted using a modified retrospective approach with a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. The cumulative effect adjustment will include recognition of the income tax consequences of intra-entity transfers of assets other than inventory that occur before the adoption date.  The Company believes its adoption will not significantly impact the Company's results of operations and financial position.

 

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash (“ASU 2016-18”), which requires that the amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-the period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 does not provide a definition of restricted cash or restricted cash equivalents. ASU 2016-18 is effective for fiscal years and interim periods beginning after December 15, 2017. The Company does not expect the adoption of ASU 2016-18 to have any impact on the consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350), Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). The new guidance eliminates Step 2 of the goodwill impairment testing which requires the fair value of individual assets and liabilities of a reporting unit to be determined when measuring goodwill impairment. The new guidance may result in different amounts of impairment that could be recognized compared to existing guidance. In addition, failing step 1 of the impairment test may not result in impairment under existing guidance. However, under the revised guidance, failing step 1 will always result in a goodwill impairment. ASU 2017-04 is to be applied prospectively for goodwill impairment testing performed in years beginning after December 15, 2019. The Company does not believe the adoption will significantly impact the Company's results of operations or financial position.

 

 

ITEM 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

 

The Company is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations. The Company’s solutions enable its clients to understand the voice of the customer with greater clarity, immediacy and depth. NRC Health’s heritage, proprietary methods, and holistic approach enable our partners to better understand the people they care for and design experiences that inspire loyalty and trust, while also facilitating regulatory compliance and the shift to population-based health management. The Company’s ability to measure what matters most and systematically capture, analyze and deliver insights based on self-reported information from patients, families and consumers is critical in today’s healthcare market. NRC Health believes that access to and analysis of its extensive consumer-driven information is becoming more valuable as healthcare providers increasingly need to more deeply understand and engage patients and consumers in an effort towards effective population-based health management.

 

The Company’s portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. NRC Health partners with clients across the continuum of healthcare services. The Company’s clients range from integrated health systems and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company believes this cross-continuum positioning is a unique and an increasingly important capability as evolving payment models drive healthcare providers and payers towards a more collaborative and integrated service model.

 

Results of Operations

 

The following table and graphs set forth, for the periods indicated, select financial information derived from the Company’s condensed consolidated financial statements expressed as a percentage of total revenue. The trends illustrated may not necessarily be indicative of future results. The discussion that follows the table should be read in conjunction with the condensed consolidated financial statements.

 

		Three months ended
		March 31,
		2017				2016
Revenue:			100.0	%			100.0	%
Operating expenses:
Direct			41.3				41.4
Selling, general and administrative			22.1				26.4
Depreciation and amortization			3.7				3.5
Total operating expenses			67.1				71.3
Operating income			32.9	%			28.7	%

 

 

 

Three Months Ended March 31, 2017, Compared to Three Months Ended March 31, 2016

 

Revenue. Revenue for the three-month period ended March 31, 2017, increased 8.6% to $30.3 million, compared to $27.9 million in the three-month period ended March 31, 2016. The increase was due to new customer sales, as well as increases in sales to the existing client base.

 

Direct expenses. Direct expenses increased 8.3% to $12.5 million for the three-month period ended March 31, 2017, compared to $11.5 million in the same period in 2016. This was due to an increase in variable expenses of $216,000 and fixed expenses of $745,000. Variable expense increased mainly due to higher contracted voice recognition technology, phone costs, and labor costs, partially offset by decreased postage, printing and paper costs due to a reduction in postage fees and changes in survey methodologies. Fixed expenses increased primarily as a result of increased salary and benefit costs in the customer service area. Direct expenses decreased as a percentage of revenue to 41.3% in the three-month period ended March 31, 2017, compared to 41.4% during the same period of 2016 as expenses increased by 8.3% while revenue for the same period increased by 8.6%.

 

Selling, general and administrative expenses. Selling, general and administrative expenses decreased 9.1% to $6.7 million for the three-month period ended March 31, 2017, compared to $7.4 million for the same period in 2016, primarily due to lower salary and benefit costs including lower incentives, commissions, and share based compensation expense totaling $434,000 and less public company related costs and legal expenses of $296,000 mainly due shelf registration fees expensed in 2016 of $177,000 and lower audit and contracted legal counsel fees. Selling, general, and administrative expenses decreased as a percentage of revenue to 22.1% for the three-month period ended March 31, 2017, from 26.4% for the same period in 2016 as expenses decreased by 9.1% while revenue for the same period increased by 8.6%.

 

Depreciation and amortization. Depreciation and amortization expenses increased to $1.1 million for the three-month period ended March 31, 2017, compared to $968,000 for the same period in 2016 primarily due to increased amortization of $177,000 from additional computer software investments, partially offset by decreased amortization of $39,000 as a result of certain intangibles becoming fully amortized. Depreciation and amortization expenses as a percentage of revenue was 3.7% for the three-month period ended March 31, 2017, and 3.5% for the same period in 2016.

 

Provision for income taxes. Provision for income taxes was $3.5 million (34.7% effective tax rate) for the three-month period ended March 31, 2017, compared to $2.5 million (31.2% effective tax rate) for the same period in 2016. The effective tax rate for the three-month period ended March 31, 2017, was higher than the rate in the same period of 2016 mainly due to higher tax benefits in 2016 from the exercise of options and vesting of restricted stock of $166,000, as well as Internal Revenue Service audit related tax adjustments that reduced tax expense in 2016 by $48,000.

 

 

Liquidity and Capital Resources

 

The Company believes that its existing sources of liquidity, including cash and cash equivalents, borrowing availability, and operating cash flows will be sufficient to meet its projected capital and debt maturity needs and dividend policy for the foreseeable future.

 

As of March 31, 2017, our principal sources of liquidity included $34.7 million of cash and cash equivalents and up to $6.5 million of unused borrowings under our revolving credit note. The amount of unused borrowings actually available under the revolving credit note varies in accordance with the terms of the agreement. Of this cash, $11.2 million was held in Canada. All of the amounts held in Canada are intended to be indefinitely reinvested in foreign operations. The amounts held outside of the U.S. are eligible for repatriation, but under current law, would be subject to U.S. federal income taxes less applicable foreign tax credits. The Company estimated at December 31, 2016, that an additional tax liability of $536,000 would become due if repatriation of undistributed earnings would occur.

 

Working Capital

 

The Company's working capital was $18.0 million and $15.6 million on March 31, 2017 and December 31, 2016, respectively. The change was primarily due to increases in trade accounts receivable of $2.7 million, cash and cash equivalents of $1.6 million, prepaid expenses of $652,000, unbilled revenue of $377,000 and decreases in accrued wages, bonus and profit sharing of $1.2 million and accrued expenses of $411,000. This was partially offset by increases in income taxes payable of $2.9 million and deferred revenue of $1.7 million. Trade accounts receivable and unbilled revenue increased due to the timing of billings and collections on new and renewal contracts. Accrued wages, bonus and profit sharing decreased due to the payment of 2016 annual bonuses in the three-month period ended March 31, 2017. Accrued and prepaid expenses changed due to the timing of vendor payments and pre-payments for services. Income taxes payable increased due to the timing of income tax payments. The Company’s working capital is significantly impacted by its large deferred revenue balances which will vary based on the timing and frequency of billings on annual agreements. The deferred revenue balances as of March 31, 2017 and December 31, 2016 were $17.2 million and $15.5 million, respectively.

 

The deferred revenue balance is primarily due to timing of initial billings on new and renewal contracts. The Company typically invoices clients for performance tracking services and custom research projects before they have been completed. Billed amounts are recorded as billings in excess of revenue earned, or deferred revenue, on the Company’s consolidated financial statements, and are recognized as income when earned. In addition, when work is performed in advance of billing, the Company records this work as revenue earned in excess of billings, or unbilled revenue. Substantially all deferred revenue and all unbilled revenue will be earned and billed respectively, within 12 months of the respective period ends.

 

 

Cash Flow Analysis

 

A summary of operating, investing, and financing activities is shown in the following table:

 

		Three Months Ended March 31,
		2017				2016
		(In thousands)
Provided by operating activities		$	8,143			$	4,367
Used in investing activities			(1,425	)			(1,084	)
Used in financing activities			(5,161	)			(20,659	)
Effect of exchange rate change on cash			86				597
Net change in cash and cash equivalents			1,643				(16,779	)
Cash and cash equivalents at end of period		$	34,664			$	25,366

 

 

Cash Flows from Operating Activities

 

Cash flows from operating activities consist of net income adjusted for non-cash items including depreciation and amortization, deferred taxes, share-based compensation and related taxes, reserve for uncertain tax positions and the effect of working capital changes.

 

Net cash provided by operating activities was $8.1 million for the three months ended March 31, 2017, which included net income of $6.5 million, plus non-cash charges (benefits) for deferred tax expense, depreciation and amortization, reserve for uncertain tax positions and non-cash stock compensation totaling $2.0 million. Changes in working capital decreased cash flows from operating activities by $381,000, primarily due to increases in trade accounts receivables and unbilled revenue, net of increases in deferred revenue, which fluctuate due to the timing and frequency of billings on new and renewal contracts. The timing of payments related to prepaid expenses and accrued expenses, wages, bonus and profit sharing also decreased operating cash flows. These decreases to cash flows were partially offset by decreases to the timing of payments related to income taxes receivable and payable, and accounts payable.

Net cash provided by operating activities was $4.4 million for the three months ended March 31, 2016, which included net income of $5.5 million, plus non-cash charges (benefits) for deferred tax expense, depreciation and amortization, reserve for uncertain tax positions and non-cash stock compensation totaling $2.2 million. Changes in working capital decreased 2016 cash flows from operating activities by $3.3 million, primarily due to increases in trade accounts receivable and income taxes receivable and payable, net of increases in deferred revenue due to the timing of billing, collections and revenue recognition on new or renewal contracts.

 

Cash Flows from Investing Activities

 

Net cash of $1.4 million and $1.1 million was used for investing activities in the three months ended March 31, 2017 and 2016, respectively, for purchases of property and equipment.

 

 

Cash Flows from Financing Activities

 

Net cash used in financing activities was $5.2 million in the three months ended March 31, 2017. Cash was used to repay borrowings under the term note totaling $816,000 and for capital lease obligations of $27,000. Cash was also used to pay $4.2 million of dividends on common stock, and to pay payroll tax withholdings related to share-based compensation of $105,000.

 

Net cash used in financing activities was $20.7 million in the three months ended March 31, 2016. Cash was used to repay borrowings under the term note totaling $594,000, to pay capital lease obligations of $25,000, to pay dividends on common stock of $18.4 million, to pay payroll tax withholdings related to share-based compensation of $147,000, and to purchase non-controlling interests in Customer-Connect LLC totaling $2.0 million. These were partially offset by cash provided from the proceeds from the exercise of stock options of $547,000.

 

The effect of changes in foreign exchange rates increased cash and cash equivalents by $86,000 in the three months ended March 31, 2017 and increased cash and cash equivalents by $597,000 for the three months ended March 31, 2016.

 

Capital Expenditures

 

Cash paid for capital expenditures was $1.4 million for the three-month period ended March 31, 2017. These expenditures consisted mainly of computer software classified in property and equipment. The Company expects similar capital expenditure purchases for the remainder of 2017 consisting primarily of computer software and hardware and other equipment to be funded through cash generated from operations.

 

Debt and Equity

 

The Company’s term note is payable in monthly installments of $212,468. Borrowings under the term note bear interest at an annual rate of 3.12%. The outstanding balance of the term note at March 31, 2017 was $2.7 million.

 

The Company also has a revolving credit note that was renewed in June 2016 to extend the term to June 30, 2017. The maximum aggregate amount available under the revolving credit note is $6.5 million, subject to a borrowing base equal to 75.0% of the Company’s eligible accounts receivable. Borrowings under the revolving credit note bear interest at a variable annual rate, with three rate options at the discretion of management as follows: (1) 2.5% plus the daily reset one-month LIBOR or (2) 2.2% plus the one-, two- or three- month LIBOR rate, or (3) the bank’s one-, two, three, six, or twelve month Money Market Loan Rate. As of March 31, 2017 the revolving credit note did not have a balance. According to the borrowing base requirements, the Company had the capacity to borrow $6.5 million as of March 31, 2017.

 

The term note and revolving credit note are secured by certain of the Company’s assets, including the Company’s land, building, accounts receivable and intangible assets. The term note and the revolving credit note contain various restrictions and covenants applicable to the Company, including requirements that the Company maintain certain financial ratios at prescribed levels and restrictions on the ability of the Company to consolidate or merge, create liens, incur additional indebtedness or dispose of assets. As of March 31, 2017, the Company was in compliance with the financial covenants.

 

The Company has capital leases for computer equipment, office equipment, printing and inserting equipment. The balance of the capital leases as of March 31, 2017 was $228,000.

 

 

Shareholders’ equity increased $2.8 million to $85.6 million at March 31, 2017, from $82.8 million at December 31, 2016. The increase was mainly due to net income of $6.5 million, share-based compensation of $450,000 and changes in the cumulative translation adjustment of $118,000. This was partially offset by dividends declared of $4.2 million.

 

 

 

Contractual Obligations

 

The Company had contractual obligations to make payments in the following amounts in the future as of March 31, 2017:

 

Contractual Obligations(1)		Total Payments				Remainder of 2017				One to Three Years				Three to Five Years				After Five Years
(In thousands)
Operating leases		$	1,350			$	448			$	796			$	106			$	--
Capital leases			243				130				81				32				--
Uncertain tax positions(2)			--				--				--				--				--
Long-term debt			2,774				1,911				863				--				--
Total		$	4,367			$	2,489			$	1,740			$	138			$	--

 

(1)	Amounts are inclusive of interest payments, where applicable.
(2)	We have $499,000 in liabilities associated with uncertain tax positions. We are unable to reasonably estimate the expected cash settlement dates of these uncertain tax positions with the taxing authorities.

 

 

 

Stock Repurchase Program

 

The Board of Directors of the Company authorized the repurchase of up to 2,250,000 class A and 375,000 class B shares of common stock in the open market or in privately negotiated transactions under a stock repurchase program that was originally approved in February 2006 and subsequently amended in May 2013. As of March 31, 2017 the remaining number of common stock shares that could be purchased under this authorization was 280,491 class A shares and 69,491 class B shares.

 

ITEM 3.     Quantitative and Qualitative Disclosures about Market Risk

 

There are no material changes to the disclosures regarding the Company’s market risk exposures made in its Annual Report on Form 10-K for the year ended December 31, 2016.

 

ITEM 4.     Controls and Procedures

 

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report, and has concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective.

 

There have been no changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the quarter ended March 31, 2017, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

PART II – Other Information

 

ITEM 1A.

Risk Factors

 

There have been no material changes to the risk factors relating to the Company set forth in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2016.

 

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

The Board of Directors of the Company authorized the repurchase of up to 2,250,000 class A and 375,000 class B shares of common stock in the open market or in privately negotiated transactions under a stock repurchase program that was originally approved in February 2006 and subsequently amended in May 2013. Unless terminated earlier by resolution of the Company’s Board of Directors, the repurchase program will expire when the Company has repurchased all shares authorized for repurchase thereunder. As of April 28, 2017, 1,969,509 shares of class A common stock and 305,509 shares of class B common stock have been repurchased under that authorization. No stock was repurchased under the program during the three-month period ended March 31, 2017.

 

 

ITEM 6.

Exhibits

 

The exhibits listed in the accompanying index of exhibits are filed as part of this Quarterly Report on Form 10-Q.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

	NATIONAL RESEARCH CORPORATION
Date: May 5, 2017	By:	/s/ Michael D. Hays
		Michael D. Hays
		Chief Executive Officer (Principal Executive Officer)
Date: May 5, 2017	By:	/s/ Kevin R. Karas
		Kevin R. Karas Senior Vice President Finance, Treasurer, Secretary and Chief Financial Officer (Principal Financial and Accounting Officer)

 

 

NATIONAL RESEARCH CORPORATION

 

EXHIBIT INDEX TO QUARTERLY REPORT ON FORM 10-Q

For the Quarterly Period ended March 31, 2017

 

Exhibit

 

 

(31.1)

Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934.

 

(31.2)

Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934.

 

(32)	Written Statement of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

 

(101)*

Financial statements from the Quarterly Report on Form 10-Q of National Research Corporation for the quarter ended March 31, 2017, formatted in eXtensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Notes to Condensed Consolidated Financial Statements, and (vi) document and entity information.

 

* In accordance with Rule 406T of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

 

-24-